Discover
URGN
UroGen Pharma Ltd.
47.10
1 x 47.10
1 x 47.42
bid
ask
+
0.79
1.70%
01:40 PM
timesize
| Ytd | 101.10% | |
| 1y | 158.21% |
45.59
day range
47.31
15.86
52 week range
48.19
| Open | 45.90 | Prev Close | 46.31 | Low | 45.59 | High | 47.31 | Mkt Cap | 2.29B |
| Vol | 426.93K | Avg Vol | 762.46K | EPS | -1.98 | P/E | -23.79 | Forward P/E | 16.81 |
| Beta | 1.57 | Short Ratio | 7.53 | Inst. Own | 102.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 36.50 | 200-d Avg | 25.89 | 1yr Est | 58.25 |
| Income Statement | |||
| Total Revenue | 72.46M | ||
| Revenues (USD) | 72.46M | ||
| Cost of Revenue | 6.57M | ||
| Gross Profit | 65.88M | ||
| Operating Expenses | 65.77M | ||
| Research and Development Expense | 17.34M | ||
| Selling, General and Administrative Expense | 48.44M | ||
| Operating Income | 111.00K | ||
| Interest Expense | 4.89M | ||
| Income Tax Expense | 5.63M | ||
| Net Income | -14.35M | ||
| Net Income Common Stock | -14.35M | ||
| Net Income Common Stock (USD) | -14.35M | ||
| Consolidated Income | -14.35M | ||
| Earnings per Basic Share | -0.28 | ||
| Earnings per Basic Share (USD) | -0.28 | ||
| Earnings per Diluted Share | -0.28 | ||
| Earning Before Interest & Taxes (EBIT) | -3.83M | ||
| Earning Before Interest & Taxes (USD) | -3.83M | ||
| Weighted Average Shares | 50.38M | ||
| Weighted Average Shares Diluted | 50.38M | ||
| Balance Sheet | |||
| Cash and Equivalents | 80.46M | ||
| Cash and Equivalents (USD) | 80.46M | ||
| Investments | 29.02M | ||
| Investments Current | 28.84M | ||
| Investments Non-Current | 178.00K | ||
| Trade and Non-Trade Receivables | 88.76M | ||
| Current Assets | 235.43M | ||
| Property, Plant & Equipment Net | 8.23M | ||
| Total Assets | 252.59M | ||
| Debt Current | 2.10M | ||
| Total Debt | 196.13M | ||
| Current Liabilities | 61.92M | ||
| Debt Non-Current | 194.03M | ||
| Total Liabilities | 384.99M | ||
| Accumulated Retained Earnings (Deficit) | -997.64M | ||
| Accumulated Other Comprehensive Income | -2.00K | ||
| Shareholders Equity | -132.40M | ||
| Shareholders Equity (USD) | -132.40M | ||
| Assets Non-Current | 17.16M | ||
| Total Debt (USD) | 196.13M | ||
| Inventory | 24.59M | ||
| Liabilities Non-Current | 323.07M | ||
| Trade and Non-Trade Payables | 39.95M | ||
| Tax Liabilities | 3.90M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 668.00K | ||
| Net Cash Flow from Financing | 500.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -30.83M | ||
| Capital Expenditure | -60.00K | ||
| Issuance (Purchase) of Equity Shares | 887.00K | ||
| Issuance (Repayment) of Debt Securities | -387.00K | ||
| Net Cash Flow from Investing | 1.67M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 1.73M | ||
| Net Cash Flow from Operations | -33.01M | ||
| Share Based Compensation | 5.33M | ||